rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome.
|
26160848 |
2015 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test.
|
26588428 |
2016 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
More c.1799T>A (p.V600E) colorectal cancers were found in the right colon [47% (47/100)], compared with c.1781A>G (p.D594G) colorectal cancers [7% (1/15), <i>P</i> = 3.7 × 10<sup>-03</sup>].
|
27815357 |
2017 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we used an automated immunohistochemistry (IHC) staining coupled with mouse monoclonal anti-BRAF V600E (VE1) primary antibody to screen the BRAF V600E mutation in 779 tumor cases, including 611 colorectal carcinomas (CRC), 127 papillary thyroid carcinomas (PTC) and 41 malignant melanomas.
|
25784606 |
2015 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Real-time polymerase chain reaction identifies the most common BRAF mutation, V600E, in frozen or paraffin-embedded colorectal cancer tissue.
|
20670148 |
2010 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Analysis of DNA mismatch repair proteins expression and BRAF V600E mutation in a subset of early- and late-onset colorectal carcinoma patients in Mexico.
|
21945875 |
2011 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We hypothesized it would be more commonly methylated and inactivated in serrated pathway colorectal cancers that are hallmarked by a BRAF V600E mutation and a methylator phenotype, compared to traditional pathway cancers that are BRAF wild type.
|
25613750 |
2015 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The absence of BRAF V600E mutation separates LLS colorectal carcinomas from MLH1-methylated colorectal carcinomas with CIMP-positive phenotype.
|
30575961 |
2019 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation.
|
26208524 |
2015 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Colorectal cancer (CRC) with the V600E mutation of B-Raf proto-oncogene serine/threonine kinase (BRAF<sup>V600E</sup>) mutation is insensitive to chemotherapy and is indicative of a poor patient prognosis.
|
30854056 |
2019 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF inhibitor vemurafenib, and subsequent MAPK pathway inhibitors trametinib and SCH772984, significantly increased SPINK1 secretion in V600E CRC cell lines Colo205 and HT-29 with a concomitant decrease in trypsin-1 and -2 secretion.
|
29193645 |
2018 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Somatic BRAF-V600E mutations in familial colorectal cancer.
|
17119056 |
2006 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
CIMP-specific inactivation of BRAF(V600E)-induced senescence and apoptosis pathways by IGFBP7 DNA hypermethylation might create a favorable context for the acquisition of BRAF(V600E) in CIMP+ colorectal cancer.
|
20027224 |
2009 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Further preclinical and clinical investigations are needed to clarify the role of non-V600E mutations in CRC.
|
30463788 |
2018 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conclude that BRAF V600E IHC is reliable for the evaluation of mutational status in colorectal carcinoma regardless of site or prior treatment history, and staining shows a high degree of intratumoral homogeneity.
|
24921639 |
2014 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The hot spot c. 1799 T>A, p.V600E gene mutation is very rarely involved in the tumorigenesis of CRC linked to Hereditary Nonpolyposis Colorectal Cancer (HNPCC).
|
17566669 |
2007 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed sporadic CRCs in Omani (of African origin, N = 61), Iranian (of Caucasian origin, N = 53) and African American (N = 95) patients for microsatellite instability, expression status of mismatched repair genes (hMLH1, hMSH2) and presence of the BRAF (V600E) mutation.
|
18718023 |
2008 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans.
|
19190129 |
2009 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In vitro studies using CRC cell lines showed an association between MGL ligand expression and the presence of BRAF(V600E).
|
26172302 |
2015 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation has been associated with worse survival in MSS CRC.
|
26376292 |
2016 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We evaluated miR-31-5p expression and gene mutations [KRAS (codon 61 or 146), NRAS (codon 12, 13, or 61), and BRAF (V600E)] in the EGFR downstream pathway in 102 CRC patients harboring KRAS (codon 12 or 13) wild-type who were treated with anti-EGFR therapeutics.
|
25472647 |
2015 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
rs121913377
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) patients receiving standard-of-care therapy is approximately two years or more if their tumors express wild-type BRAF and wild-type KRAS, median OS is less than twelve months with tumors expressing V600E-mutant BRAF and wild-type KRAS.
|
23792567 |
2013 |